nested cohort

1,2,5,8

[1]  A. McTiernan,et al.  Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Caldas,et al.  Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.

[3]  R. Laing,et al.  Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. , 2014, The Lancet. Oncology.

[4]  E. Perez,et al.  Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Gelmon,et al.  Linking toxicity to the target. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Eskander,et al.  Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer: a systematic review , 2012 .

[7]  M. van Glabbeke,et al.  Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup , 2012, European Journal of Cancer.

[8]  K. Matsuo,et al.  Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy , 2011, Cancer Chemotherapy and Pharmacology.

[9]  V. Gebski,et al.  Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer , 2011, British Journal of Cancer.

[10]  J. Bergh,et al.  A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Beral,et al.  Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy , 2011, Journal of the National Cancer Institute.

[12]  L. Leibovici,et al.  Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2010, Journal of the National Cancer Institute.

[13]  A. M. Houghton,et al.  Neutrophil Elastase-Mediated Degradation of IRS-1 Accelerates Lung Tumor Growth , 2010, Nature Medicine.

[14]  S. Mclaughlin,et al.  Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial. , 2009 .

[15]  S. Agrawal,et al.  Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens. , 2009, Oncology nursing forum.

[16]  G. Marsh,et al.  The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. , 2009, Oncology nursing forum.

[17]  H. Earl,et al.  NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life , 2008, British Journal of Cancer.

[18]  M. Barnes,et al.  Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. , 2008, Gynecologic oncology.

[19]  H. Earl,et al.  Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. , 2006, The New England journal of medicine.

[20]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[21]  H. Gurney.  I don't underdose my patients...do I? , 2005, The Lancet. Oncology.

[22]  G. Kerr,et al.  Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer , 2003, British Journal of Cancer.

[23]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Bergh,et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial , 2000, The Lancet.

[26]  J. Bergh,et al.  Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  D. Wickerham,et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K R Hess,et al.  Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. , 1995, Statistics in medicine.

[30]  F. Sinicrope,et al.  Obesity and breast cancer prognosis: weight of the evidence. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Thijs J. Hagenbeek,et al.  Inaugural Article: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes , 2010 .

[32]  M. Fliedner,et al.  Management of oral mucositis in patients with cancer. , 2005, European journal of oncology nursing : the official journal of European Oncology Nursing Society.